44% Of Large Employers Cover Weight Loss Drugs For Obesity

In 2024, coverage of the glucagon-like peptide-1 (GLP-1) class of drugs used to treat type 2 diabetes and obesity by U.S. employers rose to 44% of all large employers (those with 500 or more employees), up from 41% last year. Of the largest employers (20,000 or more employees), 64% now offer GLP-1 coverage, an increase from 56% in 2023.

Due to cost concerns, nearly all employers that cover GLP-1 obesity medications also have authorization requirements in place to ensure they are used by members who will benefit the most. The average annual cost . . .